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The immunologic interaction between the fetus and the mother is a paradoxical communication that is regulated by fetal
antigen presentation and/or by recognition of and reaction to these antigens by the maternal immune system. There have been
signiﬁcant advances in understanding of abnormalities in the maternal-fetal immunologic relationship in the placental bed that
can lead to pregnancy disorders. Moreover, immunologic recognition of pregnancy is vital for the maintenance of gestation, and
inadequate recognition of fetal antigens may cause abortion. In this paper, we illustrate the complex immunologic aspects of
human reproduction in terms of the role of human leukocyte antigen (HLA), immune cells, cytokines and chemokines, and the
balance of immunity in pregnancy. In addition, we review the immunologic processes of human reproduction and the current
immunologic therapeutic strategies for pathological disorders of pregnancy.
1.Introduction
In 1953, Medawar ﬁrst proposed the concept of immune
tolerance, giving as an example the case of the fetal allograft
[1, 2]. He addressed the hypothesis that the semiallogeneic
fetus is able to survive because the immunologic interaction
between mother and fetus is regulated and inhibited, and
that this is because of either a lack of fetal antigen expression
resulting from the anatomic separation of the mother from
the fetus or a functional suppression of maternal lympho-
cytes. The exact mechanisms required to induce immuno-
logic tolerance of the fetus are not entirely understood.
Despite close contact between fetal trophoblasts and mater-
nal immune cells, there is a lack of antigen stimulation of
maternal lymphocytes [3–5].
Successful pregnancy has been considered a biologic ex-
ample of semiallogeneic graft acceptance, in which the semi-
allogeneic fetus is protected from immune attack from the
mother. Interestingly, the so-called semiallogeneic conceptus
actually consists of the trophoblast cells at the maternal-
conceptus interface [6]. During the ﬁrst trimester of human
pregnancy, the placenta develops into a dividing villous for-
mation with diﬀerentiation of characteristic trophoblast cell
types having diﬀerent functions. Cytotrophoblast progeni-
tors found in the villi follow two diﬀerentiation pathways:
some fuse to form the multinucleated syncytiotrophoblast
layer that encases the ﬂoating villi of the placenta, providing
theinterfacewithmaternalbloodtoregulateoxygenandpro-
tein transport [7], while others follow an invasive pathway
and diﬀerentiate into extravillous trophoblast (EVT) cells
[8]. These cells migrate from the villous tips in columns
that anchor the placenta to the maternal decidua, and EVT
cells form the cytotrophoblast shield over the decidua as well
as migrating and invading the decidua. Invasive EVT cells
play an active role in the remodeling processes that occur
in the uterine spiral arteries [9]. In human hemochorial
placenta, fetal trophoblast cells appear to be in extremely
close contact with the maternal immune cells, based on2 Clinical and Developmental Immunology
the observation that EVT cells invade the maternal decidua.
Thus, immunologic interrelations between mother and fetus
during pregnancy are thought to occur in the decidua [10,
11]. The invasive competence of EVT cells is most dominant
during the ﬁrst trimester and declines afterward.
The major cellular component of the decidua is decidual
stromal cells (DSCs). DSCs exert diﬀerent immune activities
that have emerged as relevant to the immunologic interac-
tion between mother and fetus and may lead to either a
normal pregnancy or abortion [12, 13]. Recent attention has
focused on current knowledge of the eﬀects of pregnancy
on the immune response, both peripherally and in the
decidua, leading to a discussion on fetal mechanisms for
escaping maternal immune attack and the development of
immunomodulatory therapeutic strategies for reproductive
problems [14]. Understanding the immunologic processes
that occur in normal conception will signiﬁcantly improve
our awareness of pathological conditions and suggest strate-
gies to manage associated human reproductive disorders
such as abortion, preeclampsia, and preterm delivery [15].
2. Alteration of Human Leukocyte Antigen
ExpressionduringPregnancy
Human leukocyte antigens (HLAs) are also called “trans-
plantation” antigens because they comprise the most pow-
erful stimulators of graft rejection. However, novel HLAs
expressed in the fetal membranes are tolerogenic rather
than immunogenic [16, 17], and although anti-paternal
HLA antibodies are common in pregnant women, they do
no damage [18]. One of the fundamental and absorbing
paradoxes of life is the immunologic tolerance during
reproduction involving the survival and symbiosis of the
genetically distinct fetus and its mother [5]. Thus, the mech-
anisms underlying maternal tolerance are usually eﬀective
and raise the essential issue of how immune privilege might
be established under the natural conditions of pregnancy to
guarantee viability of the embryo/fetus [19–21].
The expression of major histocompatibility complex
(MHC) proteins at the interface between mother and fetus
is tightly controlled in mammalian pregnancy [22]. The
expressed MHC class I genes are subdivided into class Ia,
which includes HLA-A,- B,a n d- C and class Ib, which
includes HLA-E,- F,a n d- G.H L Ac l a s sI I( HLA-D)g e n e s
are not translated in human trophoblast cells even under
inducing conditions where they are transcribed [23, 24]a n d
MHC class II is also undetected in both villous and extra-
villous human trophoblast cells [25]. Human trophoblast
cells express one MHC class Ia molecule (HLA-C) and
all three class Ib molecules. In human placenta, the cell-
surface expression of MHC class I molecules by the fetal
trophoblast is limited to loci of low polymorphism, HLA-
G, HLA-E,a n dHLA-C [26, 27], but the fetal trophoblast
cells do not express the MHC class Ia antigens HLA-A and
HLA-B [19, 28] that are responsible for the rapid rejection
of allografts in humans. The HLA-C gene is moderately
polymorphic and could possibly stimulate maternal antifetal
acquired immunity if the paternal alleles diﬀer from the
maternal. Interactions between HLA-C and decidual natural
killer (NK) cells may also facilitate trophoblast invasion
into maternal tissue: Tilburgs et al. demonstrated that
pregnancies with an HLA-C-mismatched child induce an
increased percentage of activated T cells in decidual tissue. In
addition,HLA-C-mismatchedpregnanciesexhibitadecidual
lymphocyteresponsetofetalcellsandcontainfunctionalreg-
ulatory T cells in decidual tissue, whereas HLA-C-matched
pregnancies do not. This suggests that in uncomplicated
pregnancies, decidual T cells exclusively recognize fetal HLA-
C at the maternal-fetal boundary, but are prevented from
inducing a destructive immune response [29]. Despite this,
allelic diﬀerences at the HLA-C locus do not seem to be a
contributoryfactorininfertilityorterminationofpregnancy.
HLA-G was the ﬁrst of the HLA class Ib molecules
expressed by trophoblast cells to be identiﬁed and remains
an antigen of great interest and a focus of experimental
evaluation [19, 20, 30]. Understanding the molecular and
biochemical features of the HLA-G gene and its products
may improve our ability to determine the ways in which
HLA-G can aﬀect pregnancy [31]. Multiple reports indicate
that levels of HLA-G may predicate reproductive success [20,
32, 33]. As a consequence, fertility physicians are anxious to
identify commercially available enzyme-linked immunosor-
bent assays or other assays that will accurately report levels
of HLA-G in the blood of patients with suboptimal fertility
[31].
Although it has been proposed that HLA-G may be an
evolutionary artifact without function [34], recent studies
using HLA-G proteins from transfected cells indicate that
these proteins may regulate immune cells and thus may be
integral to immune privilege in pregnancy [20, 35]. HLA-
G proteins probably target all of the major immune cell
subsets [33, 35, 36]. Moreover, Blanco et al. showed that the
expression of HLA-G by DSC preserved their potential to
control the cytotoxic activity of NK cells against trophoblast
and the physiological decay (by apoptosis) of DSC [15].
In the following, we discuss further the complex immune
interactions of human reproduction. We describe the activ-
ities in pregnancy of lymphocytes, NK cells, uterine (u)NK
cells, chemokines, and antigen-presenting cells (APCs)
including macrophages.
3.Trophoblast CellsandImmunologicBalance
duringPregnancy
An essential issue in pregnancy is how the fetal-placental
unit escapes maternal immune rejection. Although fetal
and maternal cells interact throughout pregnancy, the fetus
naturally continues as a privileged site not subject to
rejection [37, 38]. In most of the species that have been
studied, expression of MHC molecules by trophoblast cells
is repressed, apparently as a strategy to avoid recognition
and destruction by the maternal immune system. In recent
years, studies of equine pregnancy have advanced the ﬁeld
of reproductive immunology [39]. The trophoblast cells of
the horse are unique in the combination of spatial and
temporal regulation of MHC expression that they exhibit
during placentation. The allantochorion trophoblasts, which
comprise the majority of the maternal-fetal interface, doClinical and Developmental Immunology 3
not express MHC class I proteins, although some mRNA
can be detected in these cells [40]. During a short window
in early pregnancy, the trophoblasts of the chorionic girdle
and endometrial cups transiently express very high levels
of polymorphic MHC class I antigens of both maternal
and paternal origin [41]. The transcription of both poly-
morphic and nonpolymorphic MHC class I loci in invasive
trophoblasts and the high levels of cell-surface expression
of the polymorphic antigens set apart the equine model.
Maternal and paternal MHC antigens are both expressed
on horse trophoblast, and the mare frequently produces
cytotoxic antibodies to the paternal alloantigen shortly after
chorionic girdle trophoblast invasion [41]. The expression
of HLA-G and HLA-E antigens by the trophoblast may also
inhibit cytolysis by natural killer cells [42, 43]. Bacon et al.
further demonstrated that, in the equine model, functional
alloantigen presentation by the trophoblast can be a normal
part of early pregnancy [40].
Peripheral blood lymphocytes isolated from pregnant
mares demonstrate a reduced capacity to develop into eﬀec-
tor cytotoxic T lymphocytes capable of lysing target cells
from the breeding stallion [44]. This reduction in T-cell-
mediatedalloreactivityrevertsafterparturitionorpregnancy
termination and is not observed in males or nonpreg-
nant females. Work by several groups has demonstrated
trophoblast-produced soluble factors that may create such
an environment by modulating the proliferation and blas-
togenesis of maternal lymphocytes. Extracts from day 80
placenta have been shown to inhibit the proliferation of
maternal lymphocytes, and coculture of chorionic girdle
trophoblasts with maternal lymphocytes caused a decrease
in proliferation and a reduction in cytokine production [45,
46]. In conclusion, the pregnant mare’s immune responses
to the trophoblast of her developing placenta are fascinating
in their complexity. By providing a window into the nature
of maternal-fetal interactions, the horse has illuminated
immunologic events not easily detectable in other species.
It is well recognized that there is intimate contact
between maternal tissue and the EVT cells that invade the
decidua, and that there are high numbers of diﬀerent types
of leukocytes present within the stromal compartment of the
luteal-phase endometrium, which increase in ﬁrst-trimester
decidua[10,47].Humandeciduacontainabundantimmune
cells during gestation, with more than 30% of stromal cells
in ﬁrst-trimester decidua expressing the leukocyte common
antigen CD45 [10]. There are four major populations of
decidua leucocytes present in early pregnancy: uNK cells,
macrophages, dendritic cells (DC), and T cells [48]. Among
these, the most abundant are uNK cells (CD56+CD16− NK
cells), macrophages (CD38+CD2±CD3−CD16−CD68+), and
CD3+ T cells (CD8+ and rare CD4+), while B cells are
virtually undetectable [11, 49, 50]. The increase in leukocyte
numbers during the initial stage of pregnancy suggests that
inﬂux and/or proliferation of decidual leukocytes is under
endocrine inﬂuence. Intimate contact between EVT cells
and decidual leukocytes has been demonstrated by electron
microscopy and immunohistochemistry, suggesting that
there are paracrine interactions between maternal leukocytes
and fetal cells [11, 51].
4.NK CellsanduNKCellsin
Human Reproduction
IncontrastwithTandBcells,NKcellsdonotexpresssomat-
ically rearranged antigen-speciﬁc receptors [52]. The func-
tions of NK cells are cell lysis and cytokine production, with
individual cells having single or dual competence. For exam-
ple, lysis is directed against virally infected cells and tumor
cells. Interferon (IFN)-γ, which restricts viral infection, is
a key cytokine product [53, 54]. The number of peripheral
NK cells is decreased in pregnant women compared with
nonpregnant women [55, 56], as is IFN-γ production [14].
uNK cells are essentially activated cytokine-producing
NK cells [57] that share many characteristics with NK cells.
Most peripheral NK cells express the surface marker CD16,
an immunoglobulin (Ig) receptor, and have low expression
of CD56, an adhesion molecule. In contrast, about 1%
of peripheral lymphocytes are CD16−CD56bright NK cells,
and these CD16+CD56+ NK cells express high amounts of
the vascular addressin L-selectin [58]. However, in humans,
most uNK cells are CD56bright, but lack CD16 and L-
selectin [59]. In women, uNK cells diﬀerentiate during every
menstrual cycle, 3–5 days after the luteinizing hormone
surge [60, 61] .T h eu N Kc e l l sm a yr e g u l a t et r o p h o b l a s t
invasion into the decidua, myometrium, and uterine spiral
arteries [62]. Postmitotic uNK cells are widely distributed
within the decidua basalis, commonly (more than one
quarter) associated intramurally and intraluminally with
spiral arteries. From mid gestation, the number of uNK cells
decreases. It appears that during the ﬁrst half of gestation,
uNK cells contribute to and sustain important changes in
the maternal placental bed [54] by producing various soluble
products including the angiogenic cytokines angiopoietin-
2 and vascular endothelial growth factor [62]. In summary,
uNK cells are appropriate residents of the maternal-fetal
interface because of their unique function in supporting
the adaptation of the blood vessels of the pregnant uterus
[63].
5. Macrophages inPregnancy
Macrophages present within the decidual immune cells dur-
ing pregnancy have the potential to regulate divergent de-
mands: maintenance of immune tolerance toward allogeneic
fetal antigens and defense against the constant risk of infec-
tion by ascending and blood-borne pathogens [64]. The
functional maturation of macrophages has been revisualized
in a manner analogous to the well-supported concept of T
helper (Th)1/Th2 polarization of eﬀector T cells, by sub-
categorizing macrophage eﬀector phenotypes as either M1
or M2 [65, 66]. Macrophages activated under the inﬂuence
of proinﬂammatory cytokines and lipopolysaccharide are
categorized as M1 type, secrete tumor necrosis factor (TNF)
and interleukin (IL)-12, and participate in the progression
of inﬂammation. In contrast, M2 macrophages are polarized
by exposure to a milieu containing Th2 cytokines (IL-4, IL-
10, and IL-13) and glucocorticoids [67]. M2 polarization is
characterized by enhanced expression of innate immunity
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mannose receptor, as well as an upregulation of arginase
activity, which counteracts nitric oxide synthesis [68]. In
addition, M2 macrophages exhibit increased secretion of
IL-1 receptor antagonist [69] and a reduction in IL-12
production that contributes to the functions of M2 ma-
crophages in tissue repair and anti-inﬂammation [67]. The
M2 polarization of decidual macrophages isolated from
normal pregnancies indicates that their immunosuppressive
activities are required for the maintenance of immunologic
homeostasis during pregnancy. Simultaneously, recognition
of hazardous microbes via toll-like receptors (TLRs) and C-
type lectin receptors (CLRs) on macrophages is an essential
mechanism for host defense in the decidua. Houser et al.
proposetwodistinctsubsetsofCD14+ decidualmacrophages
in ﬁrst-trimester decidual tissue, CD11cHI, and CD11cLO,
which do not ﬁt the conventional M1/M2 categorization
[70]. CD11cHI decidual macrophages express genes asso-
ciated with lipid metabolism and inﬂammation, whereas
CD11cLO decidual macrophages express genes associated
with extracellular matrix formation, muscle regulation, and
tissuegrowth.TheCD11cHI decidualmacrophagesalsodiﬀer
from CD11cLO decidual macrophages in their ability to
process protein antigens and are likely to be the major APCs
in the decidua. Moreover, these populations each secrete
bothproinﬂammatoryandanti-inﬂammatorycytokinesthat
may contribute to the balance that establishes maternal-fetal
tolerance [70].
The M2 polarization of decidual macrophages isolated
from normal pregnancies indicates that their immuno-
suppressive activities are required for the maintenance
of immunologic homeostasis during pregnancy, while the
recognition of dangerous microbes via TLRs and CLRs on
macrophages is a key mechanism for host defense in the
decidua. The remarkable phenotypic plasticity of uterine
macrophages allows a balance of these seemingly discrepant
activities, and defects in uterine macrophage function are
closelylinkedtothepathophysiologyofabnormalgestations,
including those complicated by preeclampsia and preterm
delivery [64].
6. ImmuneTolerance and the Th Milieu during
Human Reproduction
A successful pregnancy is the consequence of numerous
complex interactions between the receptive uterus and the
mature blastocyst under immunohormonal control [71,
72]. The Th1/Th2 ratio reaches a peak in the proliferative
endometrium, signiﬁcantly declines during the secretory
phase and is at its lowest level in the early pregnancy decidua
[73]. During the early phase of pregnancy, a successful
implantation occurs in a proinﬂammatory microenviron-
ment, and a Th1-type response is followed by a shift to
Th2 to control endocrine and immune interactions [74–76].
Several cytokines such as TNF-α and IL-1 induce leukemia
inhibitoryfactorexpressioninthestromaandepithelialcells,
andthroughtheirreceptorsprovideparacrinesignalstoboth
embryonic tissues and uterine epithelium during implanta-
tion [77]. Th1 responses may be suppressed during human
pregnancyviadownregulationofnuclearfactor(NF)-κBand
T-bet transcription [78]. In addition, progesterone stimu-
lates a Th2-type response, reduces inﬂammatory cytokines,
and represses (potentially deleterious) allogeneic responses,
conferring fetal survival [79, 80].
Decidual CD4+CD25+ Tr e g u l a t o r yc e l l s( T r e g s )c o n -
stitute about 14% of the total decidual CD4+ Tc e l l s
and express glucocorticoid TNF receptor-related protein,
OX40, and cytotoxic T lymphocyte antigen (CTLA)-4 [81].
CTLA-4 expression on Tregs may augment indoleamine 2,3-
dioxygenase (IDO) expression by decidual and peripheral
blood DCs and monocytes [82]. IDO is involved in maternal
tolerance of the fetus by restraining the availability of
tryptophan to T cells insituintheuterinemicroenvironment
[83]. Human pregnancy also involves expression of L-
arginase, which exhausts arginine in the fetal-placental
microenvironment, thus limiting maternal T-cell activity
[84].
While uNK cells, macrophages, and DCs aid in orches-
trating the balance between pro- and anti-inﬂammatory
milieus over the course of gestation in humans, human
decidua has also recently been shown to contain a small
population of immature myeloid DCs [85]. Tregs in the
uterus are thought to be mainly immunosuppressive. Decid-
ual CD14+ cells express HLA-DR, but low levels of the
costimulatory molecules CD80/CD86, suggesting that they
could induce Tregs. The current recognized hypothesis
predictsthatthepotentialoftrophoblasticantigenstoinduce
a natural and tolerogenic maternal response engages Tregs,
cytokines,chemokines,IDO,andgalectin-1derivedfromthe
fetoplacental unit [86–88], which suggests a possible strategy
to treat pathological pregnancy via immunoregulation.
7. The Role of Chemokines in
Successful Pregnancy
Chemokines are another important component that are
involved in the complex immune network of the fetoplacen-
talunitbyadapting normalTcelltraﬃcking andmodulating
the inﬂammatory process [89, 90]. We highlight CCL5 (also
knownasregulateduponactivation,normalTcellexpressed,
and secreted (RANTES)), a proinﬂammatory chemokine
that plays a part in the Th1 response, contributing to a
tolerogenic response at immune-privileged sites in murine
models, and which might function as an essential modulator
of alloantigen-speciﬁc T-cell responses during normal preg-
nancy [91, 92]. Successful pregnancy is accompanied by an
increase in RANTES serum levels, whereas these were found
to be diminished in patients with recurrent spontaneous
abortions [93]. In addition, Ramhorst et al. demonstrated,
after treating Ishikawa cells—a human endocervical cell
line—with recombinant RANTES and CCR5 (a receptor for
RANTES), that there was a decrease in mRNA for CXCR4
(a chemokine receptor associated with a Th2 response)
that correlated with an increase in expression of T-bet (the
main transcription factor involved in development of a Th1
response)[94].TheyalsodemonstratedthatRANTESspecif-
ically suppresses alloactivated maternal T cells [95]. Thus,
thehighlevelsofprogesteronepresentduringnormalhuman
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be predicted to promote RANTES production to levels
required for the local induction of a tolerogenic immune
response. This would suggest that RANTES may play an
important role during maternal-fetal crosstalk, allowing
trophoblast cell survival and a maternal tolerogenic response
[96].
Evidence obtained either in vitro or in vivo has shown
thatthreechemokinereceptors,structurallyrelatedtosignal-
ingreceptors,butincapableofactivatingsignaltransduction,
the Duﬀy Antigen Receptor for Chemokines (DARC), D6,
and CCX CKR, act as chemokine decoy receptors [97]. The
best-known chemokine decoy receptor is the D6 molecule, a
seven-transmembranedomain proteinthatshares30%–35%
sequence identity with signaling chemokine receptors, but
cannot induce known chemokine receptor-signaling func-
tionssuchaschemotaxis[98,99].D6recognizesthemajority
of inﬂammatory CC chemokines and targets them for degra-
dation [99]. D6is stronglyexpressed by invading trophoblast
cells and on the apical surface of syncytiotrophoblast cells
[100]. Interestingly, Wessels et al. demonstrated that D6 is
expressed in endometrial epithelium, uterine glands, and
trophoblast; furthermore, in a model of spontaneous fetal
loss in swine, a marked loss of D6 immunoreactivity was
observed in arresting versus viable littermate attachment
sites [101]. These results suggest that the absence of the
scavenging function of D6 results in increased susceptibility
to inﬂammation-driven fetal loss [102].
8. Immunomodulatory Molecules in
ThreatenedPregnancy
During pregnancy, the maternal immune system is obviously
active and, under certain conditions, may contribute to fetal
damage/death. Well-deﬁned pathological processes include
destruction of fetal erythrocytes (Rh antigen, erythroblas-
tosis) and platelets (Human platelet alloantigens (HPA)-1
and HPA-2, alloimmune thrombocytopenia) by maternal
antibodies and infections during pregnancy, where activated
macrophagessecretinghighlevelsofTh1-typecytokinesalter
the fragile cytokine balance at the maternal-fetal interface
[20, 103]. Takeshita et al. found that adipsin immunoreac-
tivity was detected either at the decidua basalis in normal
placentas or at the placental maze in absorbed placentas
[104].However,theyalsoshowedthatthequantityofadipsin
was increased in the absorbed placentas compared with the
normal placentas, suggesting that local expression of adipsin
has an eﬀect at the maternal-fetal interface and probably
plays a role in spontaneous abortion [104].
uNK cells have been suggested to have a critical function
in pregnancy by promoting decidual health, appropriate
vascularization of implantation sites, and placental size. In
the murine pregnant uterus, extravillous cytotrophoblasts
have invaded the maternal decidua. While the decidual
macrophages or DCs recognize the trophoblast debris, uNK
cells may become active and acquire a cytotoxic function like
that of peripheral NK cells, propagating an immune attack
on fetal organs and leading to abortion or premature fetal
loss [105]. Recently, upregulation of Th17 cells and their
related cytokines (e.g., IL-17 and IL-23) was observed in
the blood and decidual tissues of patients with unexpected
abortion [106]. Wang et al. also demonstrated that the
suppressive activity of Tregs on Th17 cells was decreased in
patients with unexplained recurrent miscarriages, that the
ability of Tregs to repress inﬂammatory cytokine produc-
tion may be eﬀected by direct cell-cell contact, and that
transforming growth factor-β and IL-10 could inhibit the
expression of IL-17 [107]. Thus, it is likely that investigation
of immunomodulatory molecules during pregnancy could
assist in developing strategies for prevention or treatment of
abortion or fetal loss. We herein focus on three immunoreg-
ulatory strategies: (1) induction of endogenous peroxisome
proliferator-activated receptor-γ (PPARγ) to reduce antioxi-
dant stress and its related immunomodulation; (2) delivery
of decoy receptor 3 (DcR3) to neutralize LIGHT (lym-
photoxin exhibits inducible expression and competes with
herpesvirusglycoproteinDforHVEMonTcells,LIGHTalso
knownasTL4orTNFSF14)/Fassignaling;(3)overexpression
of galectin-9 to block the T-cell immunoglobulin mucin
(TIM)-3 pathway and its potential immunomodulatory role
in threatened pregnancy.
PPARγ i sam e m b e ro ft h en u c l e a rr e c e p t o rs u p e r f a m i l y ,
a group of transcription factors that regulate expression of
their target genes upon ligand binding. Endogenous ligands
including oxidized fatty acids and prostanoids can bind to
and activate the receptor [108]. Barak et al. reviewed the
role of PPARγ in the areas of adipocyte and macrophage
biology, insulin action, bioenergetics, and inﬂammation and
somewhat surprisingly found that PPARγ plays an essential
role in placental biology [109]. PPARγ may also function
in modulating fetal membrane signals toward parturition.
In addition, Schaiﬀ demonstrated the unique aspects of
PPARγ function in trophoblasts, which may have direct
implications for the use of PPARγ ligands during pregnancy
[110]: PPARγ agonists may decrease the risk of preterm
delivery by suppressing the inﬂammatory response within
the fetal membranes. Additional research that focuses on the
mechanism of action, molecular targets, and functions of
placental PPARγ is paramount for the translation of these
potentially beneﬁcial functions of PPARγ into therapeutic
use during pregnancy [110]. Linoleic acid is a well-known
componentofmanyfoodsandispresentinvegetables,fruits,
nuts, grains, and seeds. Linoleic and linolenic acids are easily
absorbed by oral intake to allow bioavailability to the plasma
and the brain [111]. The conjugated form of linoleic acid,
cis-9, trans-11, and a well-researched PPARγ ligand was
shown to be formed naturally from linoleic acid by gut ﬂora,
especially probiotics [112]. This suggests that appropriate
nutrition, such as linoleic acids and linolenic acids combined
with probiotics that are able to upregulate PPARγ ligands,
couldprovidebeneﬁtsfavoringanuncomplicatedpregnancy.
TIM glycoproteins share common structural motifs,
including a signal peptide, Ig domain, mucin domain,
transmembrane domain, and intracellular tail, with phos-
phorylation sites [113]. TIM-3 was originally identiﬁed as
a Th1-speciﬁc cell-surface molecule that downregulates Th1
responsesthroughinducingapoptosissignalingbygalectin-9
engagement[113,114].TheseresultssuggestthatTIM-3may
modulate the Th1/Th2 balance. In addition, recent reports6 Clinical and Developmental Immunology
show that TIM-3 is also expressed on innate immune cells
such as DCs and seems to promote innate immunity [115].
Such features of TIM-3 are consistent with the paradigm
of Th1/Th2 shift and the activation of the innate immune
system in pregnancy. Zhao et al. showed that in pregnant
women, TIM-3 enhances both innate and adaptive immune
responses by means of its upregulation in innate immune
cells,andabnormalitiesofTIM-3inpregnantwomanmaybe
deleterious to a normal pregnancy. Therefore, TIM-3 may be
an indicator for predicting the risk of abortion in pregnant
women [116]. In our recent study, we demonstrated that
controlofthepathogenic Th1cellimmuneresponse through
overexpression of galectin-9 to suppress TIM-3 signaling
anddownregulateproinﬂammatorycytokineproductioncan
inhibit the progressive destruction of β cells in autoimmune
diabetes [117], a ﬁnding that may suggest a possible strategy
for treatment of threatened pregnancy.
A soluble decoy receptor, DcR3, that binds to FasL and
inhibits FasL-induced apoptosis has been identiﬁed [118],
andFasLandLIGHTareestablishedasligandsofDcR3[119,
120]. Functionally, DcR3 can block FasL/LIGHT-mediated
apoptosis leading to the escape of cells from immune attack.
TNF-like ligand 1A (TL1A), the third ligand of DcR3, is a
costimulator of T cells that promotes IL-2 responsiveness
and increases secretion of proinﬂammatory cytokines both
in vitro and in vivo. In addition, DcR3 suppresses TL1A-
induced NF-κB activation and apoptosis [121]. Of note,
Gill and Hunt postulate that placental cytotrophoblast cells
are protected from LIGHT-mediated apoptosis by both
soluble receptor DcR3 and cellular inhibitors of apoptosis-
2 to protect human cytotrophoblast cells against LIGHT-
mediated apoptosis [122]. In addition, Yen et al. demon-
strated that human gestational tissues showed diﬀerential
production of DcR3, and that decidual DcR3 protein was
lower in anembryonic than normal pregnancies [123].
We have shown the immunomodulatory and therapeutic
activity of DcR3 in various experimental autoimmune
disordersinnonobesediabeticmice[124,125],experimental
autoimmune experimental encephalomyelitis [126], and
murine autoimmune crescentic glomerulonephritis [127],
suggesting a potential activity of DcR3 in the regulation of
successful pregnancies. However, above so-called potential
immunomodulatory molecules are only the tips of icebergs
in the understandings of the complex immunopathogenic
mechanisms of threaten pregnancy. Nevertheless, further
studies are essential to clarify these hidden mysteries.
9. Conclusion
The immunologic bond between mother and fetus remains
a mystery, although current advances in molecular immuno-
biology have clariﬁed many of the parameters involved in the
fetomaternal interaction during implantation. Experimental
models provide major insights in the ﬁeld of reproductive
immunology and the immunomodulation of normal or
pathological pregnancy. However, ethical issues concerning
the study of the physiology of early pregnancy in humans,
together with the diﬃculty of generalizing animal ﬁndings
to humans, are basic impediments to the clariﬁcation of the
implantation process and its subsequent investigation [128].
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